SYRE
Aeglea BioTherapeutics Inc

2,051
Mkt Cap
$2.57B
Volume
642,203.00
52W High
$35.31
52W Low
$10.91
PE Ratio
-15.37
SYRE Fundamentals
Price
$33.47
Prev Close
$33.06
Open
$33.66
50D MA
$26.19
Beta
1.67
Avg. Volume
622,995.68
EPS (Annual)
-$3.18
P/B
4.47
Rev/Employee
$0.00
Loading...
Loading...
News
all
press releases
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Consensus Recommendation of "Buy" from Analysts
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) has earned an average recommendation of "Buy" from the nine analysts that are covering the company, MarketBeat.com reports. One analyst has...
MarketBeat·5d ago
News Placeholder
More News
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Hits New 52-Week High - Should You Buy?
Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month High - Here's What Happened...
MarketBeat·10d ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 7.2% - Still a Buy?
Spyre Therapeutics (NASDAQ:SYRE) Trading Up 7.2% - What's Next...
MarketBeat·14d ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) CEO Cameron Turtle Sells 15,000 Shares
Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) CEO Cameron Turtle sold 15,000 shares of Spyre Therapeutics stock in a transaction dated Monday, December 1st. The stock was sold at an...
MarketBeat·15d ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Sets New 12-Month High on Analyst Upgrade
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week High on Analyst Upgrade...
MarketBeat·17d ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Upgraded by Jones Trading to Buy Rating
Jones Trading upgraded shares of Spyre Therapeutics from a "hold" rating to a "buy" rating and set a $64.00 target price for the company in a research note on Monday...
MarketBeat·17d ago
News Placeholder
Spyre Therapeutics, Inc. $SYRE Shares Sold by Universal Beteiligungs und Servicegesellschaft mbH
Universal Beteiligungs und Servicegesellschaft mbH lessened its holdings in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) by 9.2% in the second quarter, according to the company in its most...
MarketBeat·22d ago
News Placeholder
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 52-Week High - Here's What Happened
Spyre Therapeutics (NASDAQ:SYRE) Reaches New 1-Year High - Time to Buy...
MarketBeat·22d ago
News Placeholder
Foresite Capital Management VI LLC Makes New Investment in Spyre Therapeutics, Inc. $SYRE
Foresite Capital Management VI LLC acquired a new stake in Spyre Therapeutics, Inc. (NASDAQ:SYRE - Free Report) during the 2nd quarter, according to its most recent disclosure with the Securities and...
MarketBeat·23d ago
News Placeholder
Spyre Therapeutics, Inc. (NASDAQ:SYRE) Receives Average Recommendation of "Buy" from Brokerages
Shares of Spyre Therapeutics, Inc. (NASDAQ:SYRE - Get Free Report) have earned an average rating of "Buy" from the eight ratings firms that are covering the stock, MarketBeat Ratings reports. One...
MarketBeat·30d ago
<
1
2
...
>

Latest SYRE News

View

Advertisement|Remove ads.

Advertisement|Remove ads.